Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Written by Emily J. Thompson, Senior Investment Analyst

SNSE-4.17%

Source: Newsfilter

Updated: Aug 05 2025

0mins

Source: Newsfilter

Clinical Trial Updates: Sensei Biotherapeutics expects to present full data from its Phase 1/2 trial of solnerstotug by the end of 2025, with promising preliminary results indicating a favorable safety profile and potential for better patient outcomes in combination with cemiplimab.
Financial Position: The company reported a cash position of $28.6 million as of June 30, 2025, which is projected to fund operations into the second quarter of 2026, alongside a reduction in net loss compared to the previous year.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like SNSE with instant alerts to capture every critical market movement.

SNSE

$9.66+Infinity%1D

Analyst Views on SNSE

About SNSE

Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.